key: cord-0739957-pc7ri7w8 authors: Taramasso, Lucia; Magnasco, Laura; Portunato, Federica; Briano, Federica; Vena, Antonio; Giacobbe, Daniele R.; Dentone, Chiara; Robba, Chiara; Ball, Lorenzo; Loconte, Maurizio; Patroniti, Nicolò; Frisoni, Paolo; D'Angelo, Raffaele; Dettori, Silvia; Mikulska, Malgorzata; Pelosi, Paolo; Bassetti, Matteo title: Clinical presentation of secondary infectious complications in COVID-19 patients in intensive care unit treated with tocilizumab or standard of care. date: 2021-08-30 journal: Eur J Intern Med DOI: 10.1016/j.ejim.2021.08.020 sha: 96c0dc6512c06bcea351205e91dacf36c54b0d35 doc_id: 739957 cord_uid: pc7ri7w8 Objectives: The hypothesis of this study is that tocilizumab should affect common signs of infection due to its immunosuppressive properties. Primary aim of the study was to investigate whether the administration of tocilizumab to critically ill patients with COVID-19, led to a different clinical presentation of infectious complications compared to patients who did not receive tocilizumab. Secondary aim was investigating differences in laboratory parameters between groups. Methods: Single-centre retrospective study, enrolling COVID-19 patients who developed a microbiologically confirmed infectious complication (ventilator associated pneumonia or bloodstream infection) after intensive care unit (ICU) admission and either treated with tocilizumab or not (controls). Results: A total of 58 patients were included, 25 treated with tocilizumab and 33 controls. Median time from tocilizumab administration to infection onset was 10 days (range 2-26). Patients were 78% male, with median age 65 years (range 45-79). At first clinical presentation of the infectious event, the frequency of hypotension (11/25, 44% vs. 11/33, 33%), fever (8/25, 32% vs. 10/33, 30%) or hypothermia (0/25,0%, vs. 2/33, 6%), and oxygen desaturation (6/25, 28% vs 4/33, 12%), as well as the frequency of SOFA score increase of ≥ 2 points (4/25, 16%,vs. 4/33, 12%) was similar in tocilizumab treated patients and controls (p>0.1 for all comparisons). Among laboratory parameters, C-Reactive Protein elevation was reduced in tocilizumab treated patients compared to controls (8/25, 32% vs. 22/33, 67%, p=0.009). Conclusion: The clinical features of infectious complications in critically ill patients with COVID-19 admitted to ICU were not affected by tocilizumab. Tocilizumab is a recombinant humanized monoclonal antibody developed against soluble and membrane-bound isoforms of the interleukin-6 (IL-6) receptor. It prevents the binding of IL-6 to its receptor, thus inhibiting the IL-6 inflammatory cascade (1) . In the first phase of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic (2, 3) , tocilizumab has been proposed to counteract the cytokine release syndrome observed in the severe forms of the SARS-CoV-2 disease (COVID-19) (1, 4) . Ever since, it has been argued whether such a powerful immune suppressor drug could attenuate or mask the clinical and laboratory manifestations of infectious complications, particularly in critically ill patients admitted to the intensive care unit (ICU) (5) . The definitive diagnosis of an infection is often challenging in the ICU where multiple causes of critical illness can confuse the clinical picture, and the severity of patients' clinical presentation often leads to an overuse of antibiotics, which is reported in up to 70% of ICU patients (6) . In patients with COVID-19, the assessment becomes even more complex because the evolution of the viral infection can cause symptoms that overlap with those of a bacterial superinfection, such as fever or respiratory and hemodynamic worsening. The overall picture may be further confused by the use of glucocorticoids, which is suggested in patients with severe COVID-19 (7, 8) . But masking fever, besides leading to an increase in neutrophils and leukocytes, is another sign that overlaps with bacterial infection. The use of tocilizumab in such populations is still under investigation due to conflicting results from several randomized clinical trials (RCTs). Although the first RCTs showed that tocilizumab did not reduce short-term mortality in COVID-19 patients (9-12), a recent meta-analysis found that it was associated with lower mortality in cohort studies (13) , with higher likelihood of providing survival advantage in hyper-inflamed COVID-19 patients when initiated before the establishment of severe respiratory failure (14, 15) . Moreover, cumulative moderate certainty evidence exists, derived from both cohort studies and RCTs, which shows that tocilizumab reduces the risk of mechanical ventilation in hospitalized COVID-19 patients (13) . Finally, the preliminary results of RECOVERY and REMAP-CAP trials found a potential benefit in critically ill patients (16,17), while a recent randomized open-label trial found that tocilizumab was associated with more adverse events and worse outcomes (18) . The guidelines for tocilizumab use are continuously being updated, and while tocilizumab was not recommended as a standard of care for COVID-19 until February 2021, the latest version of the Infectious Diseases Society of America Guidelines suggests its use in cases of severe or critical disease with elevated markers of systemic inflammation (7) . However, more information is required about its use in clinical practice and especially in critically ill patients, where the question of whether tocilizumab might affect common signs of infection due to its immunosuppressive properties remains (9, 19, 20) . Observational studies evaluating tocilizumab use, particularly in cohorts of critically ill patients, have yielded mixed results on mortality (13, (21) (22) (23) , whereas they found no significant differences in the rate of secondary infectious events or death due to non-COVID 19 infections compared with patients who did not receive tocilizumab (21) (22) (23) . However, even though patients were closely monitored for signs and symptoms of secondary infections, infection rates ranged from zero to 18%, lower than expected for critically ill patients (21) (22) (23) . This might suggest the possibility of underdiagnosis due to atypical presentations of secondary infections. In addition, the clinical and laboratory presentations of secondary infections were not specifically addressed in these studies (21) (22) (23) thus leaving a knowledge gap on this issue, which may be very important in the management of the increasing number of patients eligible for tocilizumab. The primary aim of the present study was to investigate whether the administration of tocilizumab to critically ill patients with COVID-19 led to a different clinical presentation of infectious complications compared to patients who did not receive tocilizumab. This was a single-centre retrospective case-series, conducted in two ICUs (27 and 12 beds, respectively) at San Martino Hospital -IRCCS (Genoa, Italy), a 1200-bed teaching hospital in Northern Italy. The primary aim of the study was to investigate the clinical presentation of the infectious episodes occurring in critically ill patients with COVID-19 who received tocilizumab (cases), compared with those who did not receive tocilizumab (controls). Secondary aims were describing the laboratory parameters at the occurrence of the infectious event and the microbiological etiologies. Criteria for tocilizumab use in our center have been previously laboratory (PaO₂, platelet count, bilirubin and creatinine) parameters were also used to assess sequential organ failure assessment (SOFA) score. The parameters considered for the primary endpoint, namely for describing the clinical presentation of the infectious complications, were fever or hypothermia, hypotension and oxygen desaturation. Fever was defined as body temperature >38°C, hypothermia as body temperature <36°C (25,26); hypotension was defined as a systolic blood pressure <90 mmHg in a previously normotensive patient or the increase in amine support in a patient already on treatment; oxygen desaturation as an increase of 3 cmH 2 O in the minimum positive end-expiratory pressure during 24-hour period or an increase of 20% in the minimum fraction of inspired oxygen. The laboratory parameters considered for the definition of the secondary endpoint were changes in SOFA score, leucocyte and neutrophil count, CRP, and PCT levels. The SOFA score at infection onset was compared to 24 hours earlier to assess if an increase of ≥ 2 points occurred, consistent with sepsis definition (26 The collection of anonymized data for the present study was approved by the Ethics Committee of the Liguria Region (registry number 163/2020). Informed consent was waived due to the retrospective nature of the study. During the study period, 117 patients with COVID-19 were admitted to the COVID-19-dedicated Table 1 . *as compared with values measured in the 24-48 hours before infection onset. By restricting the PCT assessment to gram-negative BSI, an increase was found in one out of eight episodes among patients on tocilizumab (12.5%) and in two out of four (50%) patients not treated with tocilizumab (p = 0.4795). The SOFA score at infection onset showed an increase of ≥ 2 points, in 4/25 (16%) patients in the tocilizumab group and in 4/33 (12%) patients in the non-tocilizumab group, p = 0.715. At multivariable analysis, the reduced frequency of CRP elevation at the infection onset was confirmed to be the only factor significantly associated with tocilizumab use after controlling for possible confounders (odds ratio for CRP elevation 0.18, 95% confidence interval 0.04-0.77, Table 3 ). white blood cell count. *as compared with values measured in the 24-48 hours before infection onset. **The multivariable model was further adjusted for WBC count and steroid use. The causative microorganisms of the infectious complications described in this study are outlined in Table 4 . After 30 days of observation, 23/57 patients died; 8 (32%) were from the tocilizumab group and 15 (45%) were from the non-tocilizumab group (p = 0.300). In critically ill patients with severe COVID-19 admitted to the ICU, we found that 1) the clinical features of infectious complications were not affected by tocilizumab, and 2) among the laboratory parameters, only CRP levels showed a different trend with reduced frequency of CRP elevation in tocilizumab-treated patients compared to non-tocilizumab-treated patients. The present study addresses an original issue that was not adequately explored by previous studies and RCTs (13) . Tocilizumab use is still under investigation, and the current guidelines suggest using it in severe and critical COVID-19 cases (24). Thus, more information can be useful in managing and identifying tocilizumab and SARS-CoV-2 complications, especially in ICU patients (13, 16) . Despite tocilizumab's immunosuppressive effect, its use did not modify the frequency of common signs of infection such as fever, hypothermia, hypotension and oxygen desaturation. However, in our series, most COVID-19 patients presented few or even no clinical signs of infection regardless of tocilizumab use. Thus, it should be noted how atypical presentations of secondary infections can make the diagnosis challenging, adding to the already high difficulty of differential diagnosis in an ICU patient. At the same time, clinicians should not rely on inflammatory indexes when they suspect infections in tocilizumab-treated patients due to the tocilizumab inhibition of the inflammatory cascade regulated by IL-6, resulting in a lack of production of acute phase reactants such as CRP (36, 37) . In fact, when focusing on laboratory parameters at the occurrence of the infectious complication, the CRP levels were different in the tocilizumab and nontocilizumab treated patients in our study, with a reduced frequency of CRP elevation in those who received tocilizumab. This finding was clearly expected due to the well-known ability of tocilizumab to mechanistically reduce CRP, as above-described (36, 37) . On the contrary, tocilizumab should not interfere with PCT production, as its release is driven in vivo, primarily by the proinflammatory cytokines tumour necrosis factor-α and IL-1ß (37), which are not directly regulated by the IL-6 cascade. In our study, the frequency of PCT elevation was comparable in the two groups of patients, and although the levels were slightly higher in the non-tocilizumab patients, the difference in trend was not statistically significant. Similarly, all the other laboratory parameters considered were comparable in tocilizumab-and non-tocilizumab-treated patients. Leucocyte and neutrophil levels seemed higher in the tocilizumab patients, but the frequency of their elevation, when compared to24-48 hours earlier, was similar in the two groups, with the difference in the baseline levels probably owing to the imbalance in steroid administration in the tocilizumab group. Thus, the results of our study emphasise that inflammatory indexes should not solely be relied on when assessing a possible diagnosis of bacterial/fungal superinfection in ICU patients. This is in accordance with previous studies in which the use of laboratory markers such as CRP or PCT elevation was not recommended to diagnose infection, sepsis or septic shock (27, 29, 38, 39) . This is more true for patients who have received tocilizumab (36, 37) . Finally, the microbiological findings were similar in the tocilizumab-and non-tocilizumab-treated patients, and despite the number being low, it reflected the epidemiology of the participating ICU and the etiologies expected in critically ill patients developing common infectious complications such as VAP and BSI during the ICU stay (6, 35, 40) . Our data suggest that in critically ill patients with severe COVID-19 disease, the immune suppression mediated by tocilizumab use did not significantly alter the clinical presentation and the laboratory parameters other than CRP in case of infectious complications. Furthermore, the common etiologies of VAP and BSI should be considered when starting an empirical treatment in ICU patients treated with tocilizumab as highlighted by the etiologies of these infectious complications described in the present study. This study has several limitations. The first limitation is the retrospective design and the low power of the study. Moreover, it is possible that some diagnoses of infectious complications were missed because of previous antibiotic administration resulting in negative cultures (41) or because they presented signs and symptoms different from those considered in this study or no symptoms at all. However, this consideration is beyond the scope of the study, as we aimed to describe the clinical presentation of confirmed cases rather than the incidence of infections. The second limitation is that, although microbiologically confirmed, the diagnoses of VAP and coagulasenegative staphylococci bacteraemia might be arbitrary, and their clinical relevance might be questioned (42) even if all the infections recorded have been treated accordingly and are, thus, considered clinically relevant by the caring physicians. Finally, the imbalance in the corticosteroid use in the case and control groups might have contributed to masking the differences in the clinical and laboratory characteristics of the two groups of patients. In conclusion, the clinical features of infectious complications in ICU patients with COVID-19 were not affected by tocilizumab use. Further, the index of suspicion of an infectious complication should always be high in critically ill patients with severe COVID-19 disease admitted to ICUs and should not only be guided by inflammatory parameters, especially in tocilizumab-treated patients. In fact, even isolated or transient symptoms should drive prompt and complete diagnostic workup to exclude possible infections. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality Clinical characteristics, management and in-hospital mortality of patients with COVID-19 In Genoa S1198743X20304845 Duration of quarantine in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a question needing an answer S019567012030102X Tocilizumab and steroid treatment in patients with COVID-19 pneumonia Risk of infections in rheumatoid arthritis patients treated with tocilizumab Bloodstream infections in critically ill patients with COVID-19 Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19 Infection Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report Efficacy of Tocilizumab in Patients Hospitalized with Covid-19 Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial Tocilizumab in Hospitalized Patients With COVID-19 Pneumonia Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation. Front Immunol Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study. The Lancet Rheumatology Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia Masked early symptoms of pneumonia in patients with rheumatoid arthritis during tocilizumab treatment: a report of two cases Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMAtteo COvid19 REgistry (SMACORE). Microorganisms [Internet Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study. The Lancet Rheumatology Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19 The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) When not to start antibiotics: avoiding antibiotic overuse in the intensive care unit. Clinical Microbiology and Infection Use of C-reactive protein to tailor antibiotic use: a systematic review and meta-analysis Pros and cons of using biomarkers versus clinical decisions in start and stop decisions for antibiotics in the critical care setting Bloodstream infections in HIV-infected patients Bloodstream infections in patients living with HIV infection in the recent cART era: did something change?". In: Exploring Complexity in Health: An Interdisciplinary Systems Approach Ventilator-associated pneumonia Clinical Practice Guidelines by the Infectious Diseases Society of America and the Pneumonia (Ventilator-associated [VAP] and non-ventilator-associated Pneumonia Incidence and Prognosis of Ventilator-Associated Pneumonia in Critically Ill Patients with COVID-19: A Multicenter Study ACTEMRA (tocilizumab) injection, for intravenous or subcutaneous use. HIGHLIGHTS OF PRESCRIBING INFORMATION Procalcitonin: a marker of infection not subverted by treatment with interleukin-6 receptor inhibition Sepsis and septic shock. Nat Rev Dis Primers The use and risks of antibiotics in critically ill patients Gram-Negatives and Candida auris during the COVID-19 Pandemic in Critically Ill Patients: One Step Back in Antimicrobial Stewardship? Microorganisms Unrevealing culture-negative severe sepsis Diagnosis of ventilator-associated pneumonia: controversies and working toward a gold standard